CD = Crohn's disease; ERCP = endoscopic retrograde cholangiopancreatography; FMT = faecal microbiota transplant; GI = gastrointestinal; HBV = hepatitis B virus; HR = hazard ratio IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; OR = odds ratio; NUC = nucleos(t)ide analogue; PPI = proton-pump inhibitor; RCT = randomised controlled trial; TNF = tumour necrosis factor; UC = ulcerative colitis.
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues Comment: Chronic HBV infection remains a major risk factor for hepatocellular carcinoma worldwide. Sustained suppression of viral replication is well known to reduce the risk for progression to cirrhosis and liver failure. HBeAg seroconversion has been established as a surrogate marker for treatment response (since complete eradication is rare), but occurs only in up to 40% of patients treated with interferon and 20% of patients treated with NUCs. This study is the first comprehensive analysis of the role of anti-HBc titre in predicting HBe seroconversion on antiviral therapy. That anti-HBc titres steadily declined on antiviral therapy suggests a relationship between immune response and treatment response in both interferon-based and NUC only therapy. Furthermore, given the high OR, anti-HBc titres may prove useful in identifying HBeAg-positive patients with the highest chance of responding. Given the retrospective nature of this study and that there are other NUCs that were not included here, further study is required. However, it is promising that a cutoff anti-HBc titre could be determined here for two treatments as different as interferon and NUC only.
Gastroenterology Research Review

TM
Gastroenterology Research Review TM
Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection Authors: Lee CH et al. Summary: Adults with recurrent or refractory C. difficile infection received either frozen (n=114) or fresh (n=118) FMT via enema in this RCT. Frozen FMT was found to be noninferior to fresh FMT for clinical resolution of diarrhoea without relapse at 13 weeks in both per-protocol (83.5% vs. 85.1% [p=0.01 for noninferiority]) and modified intent-to-treat analyses (75.0% vs. 70.3% [p<0.001 for noninferiority]), with no between-group differences in adverse or serious adverse events. An accompanying editorial highlighted questions that still need to be addressed regarding frozen FMTs in C. difficile infection.
Comment: Since the early 2000s, C. difficile infections have become more and more treatment resistant, partially due to the emergence of hypervirulent strains. FMT has been used in these circumstances, but is only available at few centres around Australia at this stage. While the procedure of FMT is straightforward, it remains logistically a complex procedure related to identifying/screening donors and timing of stool collection and preparation and costs for such processes. This has resulted in limited access of patients with severe or recurrent C. difficile infections that often belong to elderly or marginalised populations. The current study clearly establishes that frozen FMT is noninferior to fresh FMT in terms of efficacy and safety. Interestingly, the chances of clinical resolution may increase with number of FMTs and the primary endpoint was defined as "no recurrence after up to two FMTs". The number of deaths in this study (n=18; 8.7%) highlights the significant morbidity in this patient group, as none were directly related to FMT and only four (1.8%) had unresolved C. difficile infection. Notably, the follow-up timeframe of this study was short, and thus late side effects of FMT would have not been assessed. Overall, however, this well designed study shows that frozen FMT is clearly a viable option to treat C. difficile infections. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia Authors: Gómez-Torrijos E et al. Summary: Durability of response to omeprazole 40mg twice daily for 8 weeks after tapering the dosage was investigated in this prospective research involving 40 patients with PPI-responsive oesophageal eosinophilia. No symptom relapses were seen among participants in histological remission, but clinical remission was evident in half of those with relapsing oesophageal inflammation. Maintenance of complete remission was achieved at a rate of 81% following a reduction in omeprazole dosage to 40mg once daily, and among those who stayed in complete remission at this dosage, 83% continued to stay in remission when the dosage was reduced further to 20mg once daily. Asymptomatic hypertransaminasaemia and oesophageal candidiasis occurred with high doses of omeprazole in only two participants.
Comment: Eosinophilic oesophagitis is an increasingly recognised and diagnosed condition causing reflux symptoms, pain, dysphagia and food impaction. Oesophageal eosinophilia is clinically, endoscopically and histologically indistinguishable from eosinophilic oesophagitis, but has a dramatic response to PPIs. In the current study, 33% of eosinophilic oesophagitis patients were PPI responsive and thus considered oesophageal eosinophilia patients. The majority of oesophageal eosinophilia patients (>80%) remained in remission even after tapering of PPI dosage to daily and at less than half of original dosage, with a good safety profile and side effects only noted at the higher dosage. Notably, clinical remission did not necessarily mirror histological remission; i.e. endoscopic evaluation of treatment response should be mandatory.
Reference: Aliment Pharmacol Ther 2016;43 (4) Notably, only one patient died within 30 days after the procedure, and this patient had decompensated liver disease and hepatocellular carcinoma. While this study is retrospective, uncontrolled and included a very heterogeneous group of patients and procedures, the complication rates are encouraging and highlight the need to assess patients carefully on a case-by-case basis and the importance of optimising patients as much as possible prior to procedure. Given that encephalopathy was a predictor for poor outcomes, this should be assessed very specifically in the preoperative assessment.
Reference: Gastrointest Endosc 2016;83 (2) Comment: The natural history of gallstones and the likelihood of symptoms are highly controversial. This presents a growing problem for healthcare providers given the increasing number of gallstones diagnosed incidentally through increasingly common abdominal imaging for unrelated reasons. This cohort study (n=664) assessed the natural history of incidental gallstones in an urban setting with a 20-year follow-up. Importantly, only less than 20% of study subjects developed clinical events and only 8% complicated events. This was associated with larger, multiple and older gallstones. Younger age and female gender were also associated with gallstone events. Given that only less than 1 in 5 patients actually developed symptoms, incidental gallstones should not translate into an immediate treatment evaluation, particularly in those patients without aforementioned risk factors. An analysis revealed no difference between the active treatment and placebo groups for the primary outcome of adenoma recurrence on colonoscopy at 3 years (OR 0.95 [95% CI 0.61-1.48]), adverse events or secondary outcomes, and the trial was terminated early due to futility. Subgroup analyses revealed that treatment effects may be influenced by smoking status, with ORs for nonsmokers and current smokers of 0.65 and 1.70, respectively (p<0.05 interaction), but the overall interaction was not significant. An accompany editorial discussed the study and its findings.
Comment: Chemoprevention as primary prevention of colorectal cancer is a topical subject and is frequently raised by patients. Aspirin and calcium (in a vitamin D-dependent manner) alone or in combination were previously shown to decrease the risk for colorectal adenoma and cancer. This well-designed study included 1107 patients with at least one sporadic adenoma removed prior to study entry. The patients were randomised to aspirin, calcitriol and calcium therapy and assessed for adenoma recurrence during a 3-year follow-up. The study was stopped due to futility, as the combination of all three compounds had no effect on adenoma recurrence rates. However, a few comments need to be made regarding the study design and analysis. Firstly, calcium was used at lower doses than what is normally prescribed and only 75mg of aspirin was given. Secondly, given that the trial was stopped early, only a limited number of patients were evaluable (n=427) due to a high dropout rate of 61%. Finally, this study recruited patients in 109 centres across ten countries. Given the impact of equipment and endoscopists' experience on adenoma detection rates, that adenoma recurrence rates were low (25%) and that some of the involved countries do not have primary colonoscopy screening programmes, the risk for nondrug-related factors contributing to outcomes in this study is high. In summary, the current study's results should be considered with caution and in the context of other well-designed studies on chemoprevention. Exposure to acid-suppressing drugs during pregnancy and the risk of asthma in childhood Authors: Cea Soriano L et al.
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Summary: This observational cohort study investigated the relative risks of asthma in 2371 children with prenatal exposure to PPIs and/or histamine H 2 -receptor antagonists versus 7745 nonexposed children. The respective incidences of asthma in the PPI-exposed, H 2 -receptor antagonist-exposed and nonexposed cohorts were 23.88, 32.16 and 19.52 per 1000 person-years. Compared with nonexposed infants, those whose mother had received a prescription for an H 2 -receptor antagonist at any time during her pregnancy were at significantly greater risk of developing asthma (HR adjusted for prepregnancy maternal healthcare utilisation, 1.43 [95% CI 1.20-1.70]), whereas the risk in those whose mothers had been prescribed a PPI was not significantly increased (1.12 [0.88-1.44]); these associations were attenuated on additional adjustments for maternal comorbidities and other medications, but their respective statistical significances were retained (1.32 [1.05-1.64] and 1.03 [0.76-1.40], respectively).
Comment: Heartburn or gastroesophageal reflux is very common during pregnancy. H 2 -receptor antagonists are often ineffective and PPIs are increasingly used. While there have been no malformative or foetotoxic effects attributed to PPI use in pregnancy, there is some concern whether PPIs may increase the risk for childhood asthma. The current study addressed this question in an observational cohort with 2371 prenatally exposed and 7745 nonexposed children.
After adjusting for confounders, PPIs did not increase the risk for childhood asthma and H 2 -receptor antagonists showed a modest increase. Even the results for H 2 -receptor antagonists should be considered with caution given the substantial decrease with adjustments for maternal comorbidities and comedication. The advantage of the current study is the large sample size and that the cohort has been shown to be representative of the UK primary-care setting with its design validated for epidemiological studies. While requiring further validation, the results of this study are encouraging given its large sample size. Patients with IBS (Rome III criteria; all subtypes) underwent an overnight fast and then received a 400mL liquid breakfast containing lactulose 25g, and factors predictive of outcomes to this challenge were identified. The participants were assigned to groups with high-intensity (n=39) or low-intensity (n=61) GI symptoms based on the intensities of eight GI symptoms and level of digestive comfort during the challenge. Compared with the low-intensity GI symptom group, participants with high-intensity GI symptoms had significantly more severe IBS (p<0.0001), greater somatisation (p<0.01), lower quality of life scores (p<0.05) and significantly higher rectal sensitivity to random phasic distensions (p<0.05). No significant between-group difference was seen for faecal microbiota composition, exhaled gas in breath or oro-anal transit time.
Comment: IBS is one of the common GI disorders in the Western world. Visceral hypersensitivity is a typical feature of IBS and is often worsened postprandially. The current study assessed the utility of lactulose as a challenge agent to assess visceral sensitivity in IBS patients. A combined nutrient/lactulose challenge allows subgrouping of IBS patients according to their clinical symptoms independent of ROME III subtypes and reflects visceral sensitivity as measured by rectal barostat. The clustering by lactulose challenge was reflective of several scoring systems used to assess IBS severity. This challenge test (after further validation) may therefore prove useful, not only as a research tool, but also as a more physiological approach to assess visceral sensitivity and disease severity in IBS, and thus in the clinical management of IBS patients.
